Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informe3d that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Central Islip, Long Island, New York, USA, from 13th July, 2026 to 17th July, 2026 (EDT). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the Company has received 1 inspectional observation in Form 483. The Company will work closely with the USFDA and is committed to address this comprehensively within stipulated time.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1977.30 |
| Dr. Reddys Labs. | 1141.70 |
| Cipla | 1477.05 |
| Lupin | 2450.05 |
| Zydus Lifesciences | 1122.75 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: